Targeting inhibition of prognosis-related lipid metabolism genes including CYP19A1 enhances immunotherapeutic response in colon cancer
Abstract Background Lipid metabolic reprogramming in colon cancer shows a potential impact on tumor immune microenvironment and is associated with response to immunotherapy. Therefore, this study aimed to develop a lipid metabolism-related prognostic risk score (LMrisk) to provide new biomarkers and...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-04-01
|
| Series: | Journal of Experimental & Clinical Cancer Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13046-023-02647-8 |
| _version_ | 1797845700024729600 |
|---|---|
| author | Lilong Liu Min Mo Xuehan Chen Dongchen Chao Yufan Zhang Xuewei Chen Yang Wang Nan Zhang Nan He Xi Yuan Honglei Chen Jing Yang |
| author_facet | Lilong Liu Min Mo Xuehan Chen Dongchen Chao Yufan Zhang Xuewei Chen Yang Wang Nan Zhang Nan He Xi Yuan Honglei Chen Jing Yang |
| author_sort | Lilong Liu |
| collection | DOAJ |
| description | Abstract Background Lipid metabolic reprogramming in colon cancer shows a potential impact on tumor immune microenvironment and is associated with response to immunotherapy. Therefore, this study aimed to develop a lipid metabolism-related prognostic risk score (LMrisk) to provide new biomarkers and combination therapy strategies for colon cancer immunotherapy. Methods Differentially expressed lipid metabolism-related genes (LMGs) including cytochrome P450 (CYP) 19A1 were screened to construct LMrisk in TCGA colon cancer cohort. The LMrisk was then validated in three GEO datasets. The differences of immune cell infiltration and immunotherapy response between LMrisk subgroups were investigated via bioinformatic analysis. These results were comfirmed by in vitro coculture of colon cancer cells with peripheral blood mononuclear cells, human colon cancer tissue microarray analysis, multiplex immunofluorescence staining and mouse xenograft models of colon cancer. Results Six LMGs including CYP19A1, ALOXE3, FABP4, LRP2, SLCO1A2 and PPARGC1A were selected to establish the LMrisk. The LMrisk was positively correlated with the abundance of macrophages, carcinoma-associated fibroblasts (CAFs), endothelial cells and the levels of biomarkers for immunotherapeutic response including programmed cell death ligand 1 (PD-L1) expression, tumor mutation burden and microsatellite instability, but negatively correlated with CD8+ T cell infiltration levels. CYP19A1 protein expression was an independent prognostic factor, and positively correlated with PD-L1 expression in human colon cancer tissues. Multiplex immunofluorescence analyses revealed that CYP19A1 protein expression was negatively correlated with CD8+ T cell infiltration, but positively correlated with the levels of tumor-associated macrophages, CAFs and endothelial cells. Importantly, CYP19A1 inhibition downregulated PD-L1, IL-6 and TGF-β levels through GPR30-AKT signaling, thereby enhancing CD8+ T cell-mediated antitumor immune response in vitro co-culture studies. CYP19A1 inhibition by letrozole or siRNA strengthened the anti-tumor immune response of CD8+ T cells, induced normalization of tumor blood vessels, and enhanced the efficacy of anti-PD-1 therapy in orthotopic and subcutaneous mouse colon cancer models. Conclusion A risk model based on lipid metabolism-related genes may predict prognosis and immunotherapeutic response in colon cancer. CYP19A1-catalyzed estrogen biosynthesis promotes vascular abnormality and inhibits CD8+ T cell function through the upregulation of PD-L1, IL-6 and TGF-β via GPR30-AKT signaling. CYP19A1 inhibition combined with PD-1 blockade represents a promising therapeutic strategy for colon cancer immunotherapy. |
| first_indexed | 2024-04-09T17:44:20Z |
| format | Article |
| id | doaj.art-d4c1b95583854fb4a0a6dcf61444a674 |
| institution | Directory Open Access Journal |
| issn | 1756-9966 |
| language | English |
| last_indexed | 2024-04-09T17:44:20Z |
| publishDate | 2023-04-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Experimental & Clinical Cancer Research |
| spelling | doaj.art-d4c1b95583854fb4a0a6dcf61444a6742023-04-16T11:28:08ZengBMCJournal of Experimental & Clinical Cancer Research1756-99662023-04-0142112010.1186/s13046-023-02647-8Targeting inhibition of prognosis-related lipid metabolism genes including CYP19A1 enhances immunotherapeutic response in colon cancerLilong Liu0Min Mo1Xuehan Chen2Dongchen Chao3Yufan Zhang4Xuewei Chen5Yang Wang6Nan Zhang7Nan He8Xi Yuan9Honglei Chen10Jing Yang11Department of Pharmacology and Hubei Province Key Laboratory of Allergy and Immune-related Diseases, School of Basic Medical Sciences, Wuhan UniversityDepartment of Pharmacology and Hubei Province Key Laboratory of Allergy and Immune-related Diseases, School of Basic Medical Sciences, Wuhan UniversityDepartment of Pharmacology and Hubei Province Key Laboratory of Allergy and Immune-related Diseases, School of Basic Medical Sciences, Wuhan UniversityDepartment of Pharmacology and Hubei Province Key Laboratory of Allergy and Immune-related Diseases, School of Basic Medical Sciences, Wuhan UniversityDepartment of Pharmacology and Hubei Province Key Laboratory of Allergy and Immune-related Diseases, School of Basic Medical Sciences, Wuhan UniversityDepartment of Laboratory Medicine, Zhongnan Hospital of Wuhan UniversityDepartment of Pharmacology and Hubei Province Key Laboratory of Allergy and Immune-related Diseases, School of Basic Medical Sciences, Wuhan UniversityDepartment of Pharmacology and Hubei Province Key Laboratory of Allergy and Immune-related Diseases, School of Basic Medical Sciences, Wuhan UniversityDepartment of Pharmacology and Hubei Province Key Laboratory of Allergy and Immune-related Diseases, School of Basic Medical Sciences, Wuhan UniversityDepartment of Pharmacology and Hubei Province Key Laboratory of Allergy and Immune-related Diseases, School of Basic Medical Sciences, Wuhan UniversityDepartment of Pathology, School of Basic Medical Sciences, Wuhan UniversityDepartment of Pharmacology and Hubei Province Key Laboratory of Allergy and Immune-related Diseases, School of Basic Medical Sciences, Wuhan UniversityAbstract Background Lipid metabolic reprogramming in colon cancer shows a potential impact on tumor immune microenvironment and is associated with response to immunotherapy. Therefore, this study aimed to develop a lipid metabolism-related prognostic risk score (LMrisk) to provide new biomarkers and combination therapy strategies for colon cancer immunotherapy. Methods Differentially expressed lipid metabolism-related genes (LMGs) including cytochrome P450 (CYP) 19A1 were screened to construct LMrisk in TCGA colon cancer cohort. The LMrisk was then validated in three GEO datasets. The differences of immune cell infiltration and immunotherapy response between LMrisk subgroups were investigated via bioinformatic analysis. These results were comfirmed by in vitro coculture of colon cancer cells with peripheral blood mononuclear cells, human colon cancer tissue microarray analysis, multiplex immunofluorescence staining and mouse xenograft models of colon cancer. Results Six LMGs including CYP19A1, ALOXE3, FABP4, LRP2, SLCO1A2 and PPARGC1A were selected to establish the LMrisk. The LMrisk was positively correlated with the abundance of macrophages, carcinoma-associated fibroblasts (CAFs), endothelial cells and the levels of biomarkers for immunotherapeutic response including programmed cell death ligand 1 (PD-L1) expression, tumor mutation burden and microsatellite instability, but negatively correlated with CD8+ T cell infiltration levels. CYP19A1 protein expression was an independent prognostic factor, and positively correlated with PD-L1 expression in human colon cancer tissues. Multiplex immunofluorescence analyses revealed that CYP19A1 protein expression was negatively correlated with CD8+ T cell infiltration, but positively correlated with the levels of tumor-associated macrophages, CAFs and endothelial cells. Importantly, CYP19A1 inhibition downregulated PD-L1, IL-6 and TGF-β levels through GPR30-AKT signaling, thereby enhancing CD8+ T cell-mediated antitumor immune response in vitro co-culture studies. CYP19A1 inhibition by letrozole or siRNA strengthened the anti-tumor immune response of CD8+ T cells, induced normalization of tumor blood vessels, and enhanced the efficacy of anti-PD-1 therapy in orthotopic and subcutaneous mouse colon cancer models. Conclusion A risk model based on lipid metabolism-related genes may predict prognosis and immunotherapeutic response in colon cancer. CYP19A1-catalyzed estrogen biosynthesis promotes vascular abnormality and inhibits CD8+ T cell function through the upregulation of PD-L1, IL-6 and TGF-β via GPR30-AKT signaling. CYP19A1 inhibition combined with PD-1 blockade represents a promising therapeutic strategy for colon cancer immunotherapy.https://doi.org/10.1186/s13046-023-02647-8Lipid metabolismCYP19A1Tumor immune microenvironmentImmunotherapeutic responseColon cancer |
| spellingShingle | Lilong Liu Min Mo Xuehan Chen Dongchen Chao Yufan Zhang Xuewei Chen Yang Wang Nan Zhang Nan He Xi Yuan Honglei Chen Jing Yang Targeting inhibition of prognosis-related lipid metabolism genes including CYP19A1 enhances immunotherapeutic response in colon cancer Journal of Experimental & Clinical Cancer Research Lipid metabolism CYP19A1 Tumor immune microenvironment Immunotherapeutic response Colon cancer |
| title | Targeting inhibition of prognosis-related lipid metabolism genes including CYP19A1 enhances immunotherapeutic response in colon cancer |
| title_full | Targeting inhibition of prognosis-related lipid metabolism genes including CYP19A1 enhances immunotherapeutic response in colon cancer |
| title_fullStr | Targeting inhibition of prognosis-related lipid metabolism genes including CYP19A1 enhances immunotherapeutic response in colon cancer |
| title_full_unstemmed | Targeting inhibition of prognosis-related lipid metabolism genes including CYP19A1 enhances immunotherapeutic response in colon cancer |
| title_short | Targeting inhibition of prognosis-related lipid metabolism genes including CYP19A1 enhances immunotherapeutic response in colon cancer |
| title_sort | targeting inhibition of prognosis related lipid metabolism genes including cyp19a1 enhances immunotherapeutic response in colon cancer |
| topic | Lipid metabolism CYP19A1 Tumor immune microenvironment Immunotherapeutic response Colon cancer |
| url | https://doi.org/10.1186/s13046-023-02647-8 |
| work_keys_str_mv | AT lilongliu targetinginhibitionofprognosisrelatedlipidmetabolismgenesincludingcyp19a1enhancesimmunotherapeuticresponseincoloncancer AT minmo targetinginhibitionofprognosisrelatedlipidmetabolismgenesincludingcyp19a1enhancesimmunotherapeuticresponseincoloncancer AT xuehanchen targetinginhibitionofprognosisrelatedlipidmetabolismgenesincludingcyp19a1enhancesimmunotherapeuticresponseincoloncancer AT dongchenchao targetinginhibitionofprognosisrelatedlipidmetabolismgenesincludingcyp19a1enhancesimmunotherapeuticresponseincoloncancer AT yufanzhang targetinginhibitionofprognosisrelatedlipidmetabolismgenesincludingcyp19a1enhancesimmunotherapeuticresponseincoloncancer AT xueweichen targetinginhibitionofprognosisrelatedlipidmetabolismgenesincludingcyp19a1enhancesimmunotherapeuticresponseincoloncancer AT yangwang targetinginhibitionofprognosisrelatedlipidmetabolismgenesincludingcyp19a1enhancesimmunotherapeuticresponseincoloncancer AT nanzhang targetinginhibitionofprognosisrelatedlipidmetabolismgenesincludingcyp19a1enhancesimmunotherapeuticresponseincoloncancer AT nanhe targetinginhibitionofprognosisrelatedlipidmetabolismgenesincludingcyp19a1enhancesimmunotherapeuticresponseincoloncancer AT xiyuan targetinginhibitionofprognosisrelatedlipidmetabolismgenesincludingcyp19a1enhancesimmunotherapeuticresponseincoloncancer AT hongleichen targetinginhibitionofprognosisrelatedlipidmetabolismgenesincludingcyp19a1enhancesimmunotherapeuticresponseincoloncancer AT jingyang targetinginhibitionofprognosisrelatedlipidmetabolismgenesincludingcyp19a1enhancesimmunotherapeuticresponseincoloncancer |